Related Experiment Video
Updated: Oct 23, 2025

Laparoscopic Anatomical Liver Segment VII Resection with Liver Parenchymal Transection Following a Priority Approach
Published on: May 23, 2025
Dynamic changes in liver function parameters in patients with coronavirus disease 2019: a multicentre, retrospective
Qing-Lei Zeng1, Zu-Jiang Yu2, Fanpu Ji3,4
1Department of Infectious Diseases and Hepatology, The First Affiliated Hospital of Zhengzhou University, No. 1 Eastern Jianshe Road, Zhengzhou, 450052, Henan, China. zengqinglei2009@163.com.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection does not directly elevate ALT and AST but can increase GGT and TBIL. Albumin levels decreased significantly during and after SARS-CoV-2 shedding.
Area of Science:
- Hepatology
- Virology
- Infectious Diseases
Background:
- COVID-19 is associated with liver injury.
- Investigating the role of SARS-CoV-2 in liver function is crucial.
Purpose of the Study:
- To examine the clinical impact of SARS-CoV-2 on liver function tests.
- To compare liver function parameters in COVID-19 patients relative to viral shedding.
Main Methods:
- Multicentre, retrospective study design.
- Comparison of liver function tests (ALT, AST, GGT, ALP, albumin, TBIL) at various time-points.
- Baseline established 3-7 days prior to SARS-CoV-2 detection.
Main Results:
- In 70 COVID-19 patients, ALT and AST levels remained stable.
- Gamma-glutamyl transferase (GGT) and total bilirubin (TBIL) showed significant increases.
- Albumin levels decreased consistently throughout the study period.
Conclusions:
- SARS-CoV-2 does not directly cause ALT/AST elevation but may increase GGT and TBIL.
- Significant albumin decrease observed, persisting even after viral clearance.
- Chronic liver disease patients did not show increased ALT/AST during SARS-CoV-2 shedding.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...

